Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans

AAPS Journal

Volumn 13, Issue 4, 2011, Pages 565-575

  Chang, Cheng ^a   Byon, Wonkyung ^a   Lu, Yifeng ^a   Jacobsen, Leslie K ^a   Badura, Lori L ^a   Sawant Basak, Aarti ^a   Miller, Emily ^a   Liu, Jing ^a   Grimwood, Sarah ^a   Wang, Ellen Q ^a   Maurer, Tristan S ^a  

^a PFIZER INC   (United States)

Author keywords

kappa opioid receptor antagonist; PK PD modeling; proof of mechanism; translational pharmacology

Indexed keywords

2 METHYL N [[2' (PYRROLIDIN 1 YLSULFONYL)BIPHENYL 4 YL]METHYL]PROPAN 1 AMINE; KAPPA OPIATE RECEPTOR ANTAGONIST; PF 04455242; PLACEBO; PROLACTIN; SPIRADOLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG STRUCTURE; HUMAN; HUMAN EXPERIMENT; MALE; NONHUMAN; NORMAL HUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; RANDOMIZED CONTROLLED TRIAL; RAT; SPECIES DIFFERENCE;

ANIMALS; BIPHENYL COMPOUNDS; CHROMATOGRAPHY, LIQUID; HUMANS; LIMIT OF DETECTION; MALE; MODELS, THEORETICAL; NARCOTIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; SULFONAMIDES; TANDEM MASS SPECTROMETRY;

EID: 83555166044     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-011-9296-3     Document Type: Article

References (33)

1. GP Quinn J Axelrod BB Brodie 1958 Species, strain and sex differences in metabolism of hexobarbitone, amidopyrine, antipyrine and aniline Biochem Pharmacol 1 152 9 10.1016/0006-2952(58)90024-8
2. H Boxenbaum 1982 Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics J Pharmacokinet Biopharm 10 2 201 27 7120049 10.1007/BF01062336 1:CAS:528:DyaL38Xlt1Sjtbo%3D (Pubitemid 12044187)
3. A Rane GR Wilkinson DG Shand 1977 Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance J Pharmacol Exp Ther 200 2 420 4 839445 1:CAS:528:DyaE2sXhtFCru70%3D (Pubitemid 8037500)
4. I Nestorov 2007 Whole-body physiologically based pharmacokinetic models Expert Opin Drug Metab Toxicol. 3 2 235 49 17428153 10.1517/17425255.3.2.235 1:CAS:528:DC%2BD2sXktFansLg%3D (Pubitemid 47321518)
5. NA Hosea WT Collard S Cole TS Maurer RX Fang H Jones, et al. 2009 Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches J Clin Pharmacol 49 5 513 33 19299532 10.1177/0091270009333209 1:CAS:528:DC%2BD1MXlsFWmu74%3D
6. DE Mager WJ Jusko 2008 Development of translational pharmacokinetic- pharmacodynamic models Clin Pharmacol Ther 83 6 909 12 18388873 10.1038/clpt.2008.52 1:CAS:528:DC%2BD1cXlvFOrtb0%3D (Pubitemid 351704927)
7. DE Mager S Woo WJ Jusko 2009 Scaling pharmacodynamics from in vitro and preclinical animal studies to humans Drug Metab Pharmacokinet. 24 1 16 24 19252333 10.2133/dmpk.24.16 1:CAS:528:DC%2BD1MXks1Whu78%3D
8. EI Lepist WJ Jusko 2004 Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis J Vet Pharmacol Ther 27 4 211 8 15305849 10.1111/j.1365-2885.2004.00579.x 1:CAS:528:DC%2BD2cXotVCgtrY%3D (Pubitemid 39141606)
9. S Woo WJ Jusko 2007 Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin Drug Metab Dispos 35 9 1672 8 17576810 10.1124/dmd.107.015248 1:CAS:528:DC%2BD2sXpslKqsL8%3D (Pubitemid 47296063)
10. KP Zuideveld PH Van der Graaf LA Peletier M Danhof 2007 Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man Pharm Res 24 11 2031 9 17541734 10.1007/s11095-007- 9336-y 1:CAS:528:DC%2BD2sXhtV2msbrO (Pubitemid 47493572)
11. MD Lindner 2007 Clinical attrition due to biased preclinical assessments of potential efficacy Pharmacol Ther 115 1 148 75 17574680 10.1016/j.pharmthera. 2007.05.002 1:CAS:528:DC%2BD2sXntFyitbk%3D (Pubitemid 46992811)
12. D Schuster C Laggner T Langer 2005 Why drugs fail-a study on side effects in new chemical entities Curr Pharm Des 11 27 3545 59 16248807 10.2174/138161205774414510 1:CAS:528:DC%2BD2MXhtVWrs7rE (Pubitemid 41300759)
13. M Danhof EC de Lange OE Della Pasqua BA Ploeger RA Voskuyl 2008 Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research Trends Pharmacol Sci 29 4 186 91 18353445 10.1016/j.tips.2008.01.007 1:CAS:528:DC%2BD1cXksVehsrw%3D
14. Grimwood S, Lu Y, Schmidt AW, Vanase-Frawley MA, Sawant-Basak A, Miller E, McLean S, Freeman J, Wong S, McLaughlin JP, Verhoest PR. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl) methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for kappa opioid receptors. J Pharmacol Exp Ther. 2011. doi: 10.1124/jpet.111. 185108.
15. G Di Chiara A Imperato 1988 Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats J Pharmacol Exp Ther 244 3 1067 80 2855239 (Pubitemid 18090131)
16. ER Butelman TJ Harris MJ Kreek 1999 Effects of E-2078, a stable dynorphin A(1-8) analog, on sedation and serum prolactin levels in rhesus monkeys Psychopharmacology (Berl) 147 1 73 80 10.1007/s002130051144 1:CAS:528: DC%2BD3cXpslOjuw%3D%3D (Pubitemid 30010026)
17. PB Chappell JF Leckman LD Scahill MT Hardin G Anderson DJ Cohen 1993 Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: a pilot study Psychiatry Res 47 3 267 80 8396784 10.1016/0165-1781(93)90084-T 1:CAS:528:DyaK2cXhvVyksbk%3D (Pubitemid 23190385)
18. E Ur DM Wright PM Bouloux A Grossman 1997 The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man Br J Pharmacol 120 5 781 4 9138682 10.1038/sj.bjp.0700971 1:CAS:528: DyaK2sXhvFSjtLc%3D (Pubitemid 27122716)
19. N Ben-Jonathan LA Arbogast JF Hyde 1989 Neuroendocrine [corrected] regulation of prolactin release Prog Neurobiol 33 5-6 399 447 2695976 10.1016/0301-0082(89)90008-7 1:CAS:528:DyaK3cXhtlanu7k%3D (Pubitemid 20032992)
20. Verhoest PR, Sawant-Basak A, Parikh V, Hayward M, Kauffman GW, Paradis V, McHardy SF, McLean S, Grimwood S, Schmidt AW, Vanase-Frawley M, Freeman J, Van Deusen J, Cox L, Wong D, Liras S. Design and discovery of a selective small molecule kappa opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl) biphenyl-4-yl)methyl)propan-1-amine, PF-4455242). J Med Chem. 2011. doi: 10.1021/jm2006035.
21. JC Kalvass TS Maurer GM Pollack 2007 Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios Drug Metab Dispos. 35 4 660 6 17237155 10.1124/dmd.106.012294 1:CAS:528: DC%2BD2sXktVOntb4%3D (Pubitemid 46513270)
22. Y Hong DE Mager RA Blum WJ Jusko 2007 Population pharmacokinetic/ pharmacodynamic modeling of systemic corticosteroid inhibition of whole blood lymphocytes: modeling interoccasion pharmacodynamic variability Pharm Res 24 6 1088 97 17385022 10.1007/s11095-006-9232-x 1:CAS:528:DC%2BD2sXlsVGns7w%3D (Pubitemid 46798887)
23. 50, u and correlation of in vitro, preclinical, and clinical data J Pharmacol Exp Ther 323 1 346 55 17646430 10.1124/jpet.107.119560 1:CAS:528:DC%2BD2sXhtFahsb%2FN (Pubitemid 47443282)
24. DE Mager SX Lin RA Blum CD Lates WJ Jusko 2003 Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics J Clin Pharmacol 43 11 1216 27 14551176 10.1177/ 0091270003258651 1:CAS:528:DC%2BD3sXptFKitbk%3D (Pubitemid 37280793)
25. S Shimada Y Nakajima K Yamamoto Y Sawada T Iga 1996 Comparative pharmacodynamics of eight calcium channel blocking agents in Japanese essential hypertensive patients Biol Pharm Bull 19 3 430 7 8924914 10.1248/bpb.19.430 1:CAS:528:DyaK28XhvV2qtL4%3D (Pubitemid 26098577)
26. Beal SL, Sheiner LB. NONMEM user's guides. San Francisco: NONMEM Project Group, University of California; 1992.
27. FDA's Guidance for Industry: Population Pharmacokinetics. February 1999.
28. Y Yano SL Beal LB Sheiner 2001 Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check J Pharmacokinet Pharmacodyn 28 2 171 92 11381569 10.1023/A:1011555016423 1:STN:280:DC%2BD38%2FhtV2htg%3D%3D (Pubitemid 33030044)
29. Y Koch YF Chow J Meites 1971 Metabolic clearance and secretion rates of prolactin in the rat Endocrinology 89 5 1303 8 5107044 10.1210/endo-89-5-1303 1:CAS:528:DyaE38Xitleqsg%3D%3D
30. ME Molitch S Raiti G Baumann S Belknap S Reichlin 1987 Pharmacokinetic studies of highly purified human prolactin in normal human subjects J Clin Endocrinol Metab 65 2 299 304 3597709 10.1210/jcem-65-2-299 1:CAS:528: DyaL2sXkvFSntro%3D (Pubitemid 17103014)
31. A Pfeiffer W Knepel S Braun HD Meyer H Lohmann V Brantl 1986 Effects of a kappa-opioid agonist on adrenocorticotropic and diuretic function in man Horm Metab Res 18 12 842 8 3028922 10.1055/s-2007-1012453 1:CAS:528: DyaL2sXhvVyrsb4%3D (Pubitemid 17196588)
32. GH Rimoy NK Bhaskar DM Wright PC Rubin 1991 Mechanism of diuretic action of spiradoline (U-62066E)-a kappa opioid receptor agonist in the human Br J Clin Pharmacol 32 5 611 5 1659438 1:CAS:528:DyaK38XhsFKjtw%3D%3D
33. B Meibohm H Derendorf 2002 Pharmacokinetic/pharmacodynamic studies in drug product development J Pharm Sci 91 1 18 31 11782894 10.1002/jps.1167 1:CAS:528:DC%2BD38Xmslyitg%3D%3D (Pubitemid 34074464)